Lumexa Imaging (NASDAQ:LMRI) Rating Increased to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded Lumexa Imaging from “hold” to “buy.” MarketBeat reports a consensus “Moderate Buy” rating and an average price target of $16.00.
• LMRI shares opened at $12.02, with a $1.15 billion market capitalization, a 52-week range of $6.45 to $19.45, and a negative P/E ratio of -20.37.
• Director Brett Brodnax purchased 35,000 shares for approximately $253,750, while several institutional investors—including Jupiter Topco and T. Rowe Price—recently established or increased positions.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Sunday.

Several other brokerages have also issued reports on LMRI. Deutsche Bank Aktiengesellschaft set a $16.00 price target on Lumexa Imaging in a research note on Thursday. Barclays reduced their price objective on shares of Lumexa Imaging from $15.00 to $9.00 and set an "overweight" rating for the company in a research report on Wednesday, May 20th. Finally, Weiss Ratings upgraded shares of Lumexa Imaging from a "sell (e)" rating to a "sell (d)" rating in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.00.

Lumexa Imaging Stock Down 1.5%

Shares of LMRI stock opened at $12.02 on Friday. The firm has a market capitalization of $1.15 billion and a P/E ratio of -20.37. Lumexa Imaging has a 1 year low of $6.45 and a 1 year high of $19.45. The firm's fifty day moving average price is $10.85 and its two-hundred day moving average price is $10.91. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.43.

Insider Activity at Lumexa Imaging

In related news, Director Brett Brodnax bought 35,000 shares of the company's stock in a transaction dated Tuesday, May 19th. The shares were bought at an average price of $7.25 per share, for a total transaction of $253,750.00. Following the completion of the acquisition, the director directly owned 62,027 shares of the company's stock, valued at $449,695.75. This trade represents a 129.50% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Lumexa Imaging

A number of hedge funds and other institutional investors have recently modified their holdings of LMRI. Jupiter Topco LLC bought a new position in Lumexa Imaging during the second quarter valued at $24,269,000. Janus Henderson Group PLC increased its position in Lumexa Imaging by 5.4% in the first quarter. Janus Henderson Group PLC now owns 2,100,356 shares of the company's stock worth $18,063,000 after buying an additional 107,903 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in shares of Lumexa Imaging in the fourth quarter valued at $37,139,000. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Lumexa Imaging in the fourth quarter valued at $27,750,000. Finally, ArrowMark Colorado Holdings LLC purchased a new position in shares of Lumexa Imaging during the 4th quarter valued at $27,750,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source